文献速递核素与放射性配体治疗放射性药物与辐射防护

接受[177Lu]Lu-PSMA-617治疗患者出院后家庭废物处置的辐射安全考量

Radiation Safety Considerations of Household Waste Disposal After Release of Patients Who Have Received [177Lu]Lu-PSMA-617.
PubMed 文献 · J Nucl Med · 2023-07-13

本文讨论转移性前列腺癌患者接受[177Lu]Lu-PSMA-617治疗后因尿失禁可能产生污染固体废物的问题,评估将污染废物排入普通家庭垃圾流相对于其他废物管理策略的相对辐射安全优势,并指出延长患者留院至首次排尿或过夜可适度减少家庭污染废物量,但不能完全替代患者废物管理策略。

要点

  • 转移性前列腺癌患者接受放射性药物治疗时尿失禁风险较高,可能产生需患者在家管理的污染固体废物。
  • 延长留院至首次排尿或过夜可适度减少家庭污染废物量,但无法完全消除患者废物管理需求。
  • 本文评估将污染废物排入普通家庭垃圾流相对于其他管理策略的相对辐射安全优势。

核心结论

  • 将污染废物排入普通家庭垃圾流相对于其他废物管理策略具有相对辐射安全优势,但延长留院至首次排尿或过夜不能完全替代患者废物管理策略。

研究设计与样本

  • 本文为简讯(brief communication),评估接受[177Lu]Lu-PSMA-617治疗的转移性前列腺癌患者出院后家庭污染固体废物不同处置策略的相对辐射安全。

主要发现

  • 转移性前列腺癌患者因既往局部治疗并发症,接受放射性药物治疗时尿失禁发生率高于其他群体,可能产生污染固体废物。
  • 延长患者留院至首次排尿或过夜可适度减少患者在家管理的污染废物量,但不能完全消除患者废物管理策略的需求。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with metastatic prostate cancer are more likely than other groups to present for radiopharmaceutical therapy with urinary incontinence due to complications from prior local prostate cancer treatment. A consequence of urinary incontinence in patients receiving radiopharmaceutical therapy is the potential production of contaminated solid waste, which must be managed by the licensee and, at home, managed by and disposed of by the patient. Prolonging the patient stay in the treating facility after radiopharmaceutical therapy administration, until the first urinary void or potentially overnight, may moderately reduce the quantity of contaminated waste being managed by the patient at home. However, this approach does not fully mitigate the need for a patient waste-management strategy. In this brief communication, the relative radiation safety merits of contaminated waste disposal in the normal household waste stream in comparison to other waste management strategies are evaluated.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Graves SA. Radiation Safety Considerations of Household Waste Disposal After Release of Patients Who Have Received [177Lu]Lu-PSMA-617. J Nucl Med. 2023. PMID: 37442601. doi:10.2967/jnumed.123.265750

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。